Low Molecular Weight Protamine (LMWP) as Nontoxic Heparin/Low Weight Heparin Antidote (I): Preparation and Characterization

Low Molecular Weight Protamine (LMWP) as Nontoxic Heparin/Low Weight Heparin Antidote (I): Preparation and Characterization
Submitted: March 1, 2001; Accepted: June 7, 2001; Published: July 11, 2001
Li-Chien Chang
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan
Hsiao-Feng Lee, ZhiQiang Yang, and Victor C. Yang
College of Pharmacy, The University of Michigan, Ann Arbor, MI 48109-1065
ABSTRACT
Low molecular weight protamine (LMWP) appears to be a promising solution for heparin neutralization without the protamineassociated catastrophic toxic effects. The feasibility of this hypothesis was proven previously by using a peptide mixture produced from proteolytic digestion of protamine. To further examine the utility of this compound as an ultimate nontoxic protamine substitute, detailed studies on the purification and characterization of LMWP including the precise amino acid sequence, structure-function relationship, and possible mechanism were conducted. A number of LWMP fragments, composed of highly cationic peptides with molecular weights ranging from 700 to 1900 d, were prepared by digestion of native protamine with the protease thermolysin. These fragments were fractionated using a heparin affinitychromatography, and their relative binding strengths toward heparin were elucidated. Five distinct fractions were eluted at NaCl concentration ranging from 0.4 to 1.0 M and were denoted as TDSP1 to TDSP5, in increasing order of eluting ionic strength.
Among these 5 fractions, TDSP4 and TDSP5 contained 3 LMWP peptide fragments, and they were found to retain the complete heparinneutralizing function of protamine. By using a peptide mass spectrometry (MS) fingerprint mapping technique, the amino acid sequences of the microheterogeneous LMWP fragments in all these 5 elution fractions were readily identified. A typical structural scaffold made by arginine clusters in the middle and nonarginine residues at the N-terminal of the peptide sequence was observed for all these
LMWP fragments. By aligning the sequences withthe potency in heparin neutralization of these LMWP fragments, it was found that retention of potency similar to that of protamine required the presence of at least 2 arginine clusters in the LMWP fragments;
such as the sequence of VSRRRRRRGGRRRR seen in the most potent LMWP fraction-TDSP5. The above finding was further validated by using a synthetic LMWP analogue-CRRRRRRR-and it was found that its heparin-neutralizing ability was increased by changing from a monomeric to a dimeric structure of this analogue peptide. Based on these results, the structural requirement for a compound to function as an effective heparin antidote and the possible mechanism involved in `heparin neutralization were established.
Complete paper can be viewed online.